


ABSTRACT OF THE DISCLOSURE

Compounds of formula (I):



wherein

R^1 represents optionally substituted C_{4-12} alkyl, optionally substituted C_{2-6} alkylaryl, or optionally substituted 5- or 6- membered aryl or heteroaryl;

Z represents a bond, CH_2 , O, S, SO , SO_2 , NR^4 , OCR^4R^5 , CR^4R^5O , or Z , R^1 and Q together form an optionally substituted fused tricyclic group;

Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring;

X represents COR^3 or $N(O R^8)COR^9$;

R^2 represents SO_2R^{10} or $SO_2NR^{10}R^{11}$;

R^3 represents OR^6 , NR^6R^7 or NR^6OH ;

R^4 and R^5 each independently represents H, C_{1-6} alkyl or C_{1-4} alkylaryl;

R^6 and R^7 each independently represents H, C_{1-6} alkyl, or C_{1-6} alkyl substituted with one or more heteroaryl groups, or R^6 and R^7 together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N;

R^8 and R^9 each independently represents H or C_{1-6} alkyl;

R^{10} and R^{11} each independently represents H or C_{1-6} alkyl; and

and physiologically functional derivatives thereof, with the exception of N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described.